Long-term clinical experience with the omnicarbon prosthetic valve

Torregrosa, Salvador; Gómez-Plana, Jesús; Valera, Francisco; Maroñas, J; García‐Sánchez, Francisco; Peris, José Luis Aguilar; Frı́as, Ramón; Caffarena, José M.

doi:10.1016/s0003-4975(99)00557-3

Cited by 20 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thromboembolism (including transient ischemia) was virtually absent in this study, despite evidence of moderate and lower‐than‐expected anticoagulation therapy intensity. The low rate of thromboembolic complications in this study is corroborated by long‐term reports from European and Japanese centers 4,5,8‐11 . Researchers at the Mayo Clinic reported that the first 3 months following valve replacement have the highest hazard for thromboembolism 17 .…”

Section: Discussionsupporting

confidence: 78%

“…The low rate of thromboembolic complications in this study is corroborated by long-term reports from European and Japanese centers. 4,5,[8][9][10][11] Researchers at the Mayo Clinic reported that the first 3 months following valve replacement have the highest hazard for thromboembolism. 17 However, our data do not support this finding.…”

Section: Discussionmentioning

confidence: 99%

“…tions published similar experiences. [5][6][7][8][9][10][11] This all-carbon monoleaflet valve appears to have tendency toward a lower thromboembolic rate.…”

mentioning

confidence: 99%

See 2 more Smart Citations

A Six-Year Experience with the Omnicarbon Valve in North American Patients

Carrier¹,

Teijeira²,

Greentree³

et al. 2004

Journal of Cardiac Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Six-Year Experience with the Omnicarbon Valve in North American Patients

Carrier¹,

Teijeira²,

Greentree³

et al. 2004

Journal of Cardiac Surgery

View full text Add to dashboard Cite

show abstract

“…Several bileaflet and tilting prosthetic heart valves are available, and surgeons choose some of them for valve replacement according to their own preference and the informed consent of patients. Many midterm and long-term clinical results show excellent performances of these mechanical prostheses (1)(2)(3)(4)(5)(6)(7)(8)(9)(10). However, clinical results in Japan with the Bicarbon prosthetic heart valve (11) (Sorin Biomedica Cardio, Saluggia, Italy) have not been investigated enough to evaluate its performance here.…”

mentioning

confidence: 99%

Single‐Center Experience with the Bicarbon Bileaflet Prosthetic Heart Valve in Japan

et al. 2002

View full text Add to dashboard Cite

We analyzed midterm results using the Bicarbon valve in a single center. Forty-four patients had aortic valve replacement (AVR), 48 had mitral valve replacement (MVR), and 13 had both aortic and mitral valve replacement (DVR). The mean age of the 105 patients was 61.2 +/- 11.3 years. The mean follow-up was 1.8 +/- 1.1 years with a cumulative follow-up of 188 patient-years. There were 5 early deaths (4.7%: 4 in the AVR group and 1 in the MVR group) and 5 late deaths (2.7% per patient-year: 3 malignancy, 1 cerebral hemorrhage, 1 myocardial infarction). Survival at 3 years was 91 +/- 4% in the AVR group, 92 +/- 5% in the MVR group, and 66 +/- 23% in the DVR group. The linearized incidence of thromboembolic complications, hemorrhagic complications, and paravalvular leaks in all patients was 1.06 +/- 2.34%, 1.60 +/- 2.53%, and 0.53 +/- 2.22% per patient-year, respectively. No other complications were observed. In conclusion, the Bicarbon prosthetic heart valve has shown excellent clinical results associated with a low incidence of valve-related complications.

show abstract

“…13 Since then, a wide variety of new valve designs and developments have been introduced, with caged-ball valves appearing during the 1960s [14][15][16] and tilting-disk valves during the early 1970s. [17][18][19][20] Clinical experiences with the hinge bileaflet prosthesis were first reported in the 1960s. [21][22] The St Jude valve was first implanted by Nicoloff on October 3, 1977 [23][24] and received FDA approval in 1983.…”

Section: Commentmentioning

confidence: 99%